NF-κB activating gene

• US 7,227,007 B2
• Filed: 07/11/2003
• Issued: 06/05/2007
• Est. Priority Date: 12/28/2000
• Status: Expired due to Fees

• Current Assignee: Asahi Kasei Pharma Corporation (Asahi Kasei Corporation)
• Original Assignee: Asahi Kasei Pharma Corporation (Asahi Kasei Corporation)
• Inventors: Matsuda, Akio, Nagano, Yukiko, Muramatsu, Shuji, Honda, Goichi
• Primary Examiner(s): BORIN, MICHAEL L
• Application Number:
  US10/617,217
• Publication Number:
  US 20040081986A1
• Time in Patent Office: 1,425 Days
• Field of Search: 536/23.1, 530/350
• US Class Current: 536/23.1
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: C07K 14/4702 Regulators; Modulating activity
• CPC Class Codes: C07K 14/4705 stimulating, promoting or activating activity
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C12N 2503/02 Drug screening
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 2800/24 Immunology or allergic disorders
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
• CPC Class Codes: G01N 33/6872 Intracellular protein regulatory factors and their receptors, e.g. including ion channels
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Provided are proteins having NF-κB activity, which are used for diagnosing, treating or preventing diseases associated with the excessive activation or inhibition of NF-κB. Using plasmid pNFκB-Luc, cDNA encoding a protein capable of activating NF-κB has been cloned from a cDNA library constructed from human lung fibroblasts, and the DNA sequence and the deduced amino acid sequence determined. The protein, the DNA encoding the protein, a recombinant vector containing the DNA, and a transformant containing the recombinant vector are useful for screening a substance inhibiting or promoting NF-κB activation.

Claims

1. An isolated polynucleotide which comprises a nucleotide sequence encoding a protein that activates NF-κ

B and selected from the group consisting of;

(a) a protein which comprises an amino acid sequence represented by SEQ ID NO;

87.

4. An isolated polynucleotide comprising a nucleotide sequence which encodes a protein that activates NF-κ

B and has at least 95% identity to the polynucleotide sequence according to claim 1 over the entire length thereof.

6. A recombinant vector which comprises a polynucleotide according to any one of claims 1 to 4.

7. A transformed cell which comprises the recombinant vector according to claim 6.

8. A process for producing a protein comprising,

(a) culturing a transformed cell comprising the isolated polynucleotide according to any one of claims 1 to 4 under conditions providing expression of the encoded protein;

and

(b) recovering the protein from the culture product.

9. A method for screening compounds in respect of activity to inhibit or promote NF-κ

B activation, which comprises the steps of;

(a) providing a cell with a gene comprising a polynucleotide according to claim 1, 2 or 3 encoding a protein that activates NF-κ

B, and a component that provides a detectable signal associated with activation of NF-κ

B;

(b) culturing a transformed cell under conditions, which permit the expression of the gene in the transformed cell;

(c) contacting the transformed cell with one or more compounds;

(d) measuring the detectable signal; and

(e) isolating or identifying an activator compound and/or an inhibitor compound by measuring the detectable signal.

2. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

(a) a polynucleotide sequence represented by SEQ ID NO;

88;

(b) a polynucleotide sequence encoding a protein that activates NF-κ

B and hybridizing under stringent conditions with a polynucleotide having a polynucleotide sequence complementary to the polynucleotide sequence of (a).

5. An isolated polynucleotide comprising a nucleotide sequence which encodes a protein that activates NF-κ

B and has at least 95% identity to the polynucleotide sequence according to claim 2 or 3 over the entire length thereof.

10. A recombinant vector which comprises a polynucleotide according to claim 5.

11. A transformed cell which comprises the recombinant vector according to claim 10.

3. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence represented by a coding region in SEQ ID NO;

88;

(b) a nucleotide sequence encoding a protein that activates NF-κ

B and hybridizing under stringent conditions with a polynucleotide having a polynucleotide sequence complementary to the polynucleotide sequence of (a).